Partnership
Cenix BioScience GmbH, a specialist RNA interference (RNAi) contract research organisation, signed a research agreement to support Boehringer Ingelheim in target discovery in the field.
Dresden-based Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing, with high-content phenotypic analyses in a genome-scale screen using cultured human cells. Microscopy-based assays developed by Cenix will be used to complement proprietary assays developed at Boehringer Ingelheim, to generate detailed insights into the cellular functions and loss-of-function phenotypes of the genes under analysis.
Such RNAi datasets provide a highly predictive and cost-effective basis for mining the human genome to discover and prioritise targets for drug discovery in a wide range of diseases.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
